Researchers are to begin trials on the effectiveness of an anti-inflammatory drug in treating COVID-19 symptoms in care homes.
Up to 750 patients from community care settings will take part in the trials of the anti-tumour necrosis factor (anti-TNF) drug, adalimumab, following evidence that patients taking the drugs are less likely to be admitted to hospital.
The AVID-CC trial is funded by the COVID-19 Therapeutics Accelerator, an initiative set up by Wellcome, the Bill and Melinda Gates Foundation, and Mastercard, with support from an array of public and philanthropic donors.
“The observed potential of anti-TNF drugs has prompted us to conduct a study in patients in community care to see whether treatment with the anti-TNF drug adalimumab reduces the progression to severe or critical disease or death in COVID-19 patients,” said Prof Duncan Richards, Professor of Clinical Therapeutics, University of Oxford.
“We think anti-TNF drugs could be an important treatment for COVID-19 and are very grateful for the support of the COVID-19 Therapeutics Accelerator, which will allow us to find out. I would also like to thank Sandoz Ltd for provision of adalimumab. We are also looking forward to working with Sensyne Health to collect additional information on patients’ clinical status through their app. Subject to the necessary approvals we hope to start recruiting patients in late October.”
The study will be delivered by Hospital at Home teams around the UK. Hospital at Home is a relatively new service in which hospital-based teams reach out into the community to deliver more complex treatment interventions while avoiding the need for admission to hospital.